Cargando…
Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared propertie...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093243/ https://www.ncbi.nlm.nih.gov/pubmed/33941777 http://dx.doi.org/10.1038/s41467-021-22643-w |
_version_ | 1783687775678103552 |
---|---|
author | Verginelli, Federica Pisacane, Alberto Gambardella, Gennaro D’Ambrosio, Antonio Candiello, Ermes Ferrio, Marco Panero, Mara Casorzo, Laura Benvenuti, Silvia Cascardi, Eliano Senetta, Rebecca Geuna, Elena Ballabio, Andrea Montemurro, Filippo Sapino, Anna Comoglio, Paolo M. Boccaccio, Carla |
author_facet | Verginelli, Federica Pisacane, Alberto Gambardella, Gennaro D’Ambrosio, Antonio Candiello, Ermes Ferrio, Marco Panero, Mara Casorzo, Laura Benvenuti, Silvia Cascardi, Eliano Senetta, Rebecca Geuna, Elena Ballabio, Andrea Montemurro, Filippo Sapino, Anna Comoglio, Paolo M. Boccaccio, Carla |
author_sort | Verginelli, Federica |
collection | PubMed |
description | Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared properties. These cells can be isolated in vitro (agnospheres) and propagated in vivo by serial transplantation, displaying high tumorigenicity. After subcutaneous engraftment, agnospheres recapitulate the CUP phenotype, by spontaneously and quickly disseminating, and forming widespread established metastases. Regardless of different genetic backgrounds, agnospheres invariably display cell-autonomous proliferation and self-renewal, mostly relying on unrestrained activation of the MAP kinase/MYC axis, which confers sensitivity to MEK inhibitors in vitro and in vivo. Such sensitivity is associated with a transcriptomic signature predicting that more than 70% of CUP patients could be eligible to MEK inhibition. These data shed light on CUP biology and unveil an opportunity for therapeutic intervention. |
format | Online Article Text |
id | pubmed-8093243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80932432021-05-11 Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition Verginelli, Federica Pisacane, Alberto Gambardella, Gennaro D’Ambrosio, Antonio Candiello, Ermes Ferrio, Marco Panero, Mara Casorzo, Laura Benvenuti, Silvia Cascardi, Eliano Senetta, Rebecca Geuna, Elena Ballabio, Andrea Montemurro, Filippo Sapino, Anna Comoglio, Paolo M. Boccaccio, Carla Nat Commun Article Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared properties. These cells can be isolated in vitro (agnospheres) and propagated in vivo by serial transplantation, displaying high tumorigenicity. After subcutaneous engraftment, agnospheres recapitulate the CUP phenotype, by spontaneously and quickly disseminating, and forming widespread established metastases. Regardless of different genetic backgrounds, agnospheres invariably display cell-autonomous proliferation and self-renewal, mostly relying on unrestrained activation of the MAP kinase/MYC axis, which confers sensitivity to MEK inhibitors in vitro and in vivo. Such sensitivity is associated with a transcriptomic signature predicting that more than 70% of CUP patients could be eligible to MEK inhibition. These data shed light on CUP biology and unveil an opportunity for therapeutic intervention. Nature Publishing Group UK 2021-05-03 /pmc/articles/PMC8093243/ /pubmed/33941777 http://dx.doi.org/10.1038/s41467-021-22643-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Verginelli, Federica Pisacane, Alberto Gambardella, Gennaro D’Ambrosio, Antonio Candiello, Ermes Ferrio, Marco Panero, Mara Casorzo, Laura Benvenuti, Silvia Cascardi, Eliano Senetta, Rebecca Geuna, Elena Ballabio, Andrea Montemurro, Filippo Sapino, Anna Comoglio, Paolo M. Boccaccio, Carla Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition |
title | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition |
title_full | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition |
title_fullStr | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition |
title_full_unstemmed | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition |
title_short | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition |
title_sort | cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to mek inhibition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093243/ https://www.ncbi.nlm.nih.gov/pubmed/33941777 http://dx.doi.org/10.1038/s41467-021-22643-w |
work_keys_str_mv | AT verginellifederica cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT pisacanealberto cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT gambardellagennaro cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT dambrosioantonio cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT candielloermes cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT ferriomarco cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT paneromara cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT casorzolaura cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT benvenutisilvia cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT cascardieliano cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT senettarebecca cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT geunaelena cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT ballabioandrea cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT montemurrofilippo cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT sapinoanna cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT comogliopaolom cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition AT boccacciocarla cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition |